Why comparing your AI MedTech solution to the status quo isn’t enough for payer approval.
FDA clearance is a milestone—not the finish line. Why reimbursement hurdles follow right after.
A breakdown of the finalized TCET rule and what it means for Breakthrough Devices.
A review of what peer-reviewed publications reveal about payer adoption of AI tools.